Cited by 52Acute Kidney Injury ResearchMolecular Sensors and Ion DetectionLuminescence and Fluorescent Materials

Real-Time Monitoring Renal Impairment Due to Drug-Induced AKI and Diabetes-Caused CKD Using an NAG-Activatable NIR-II Nanoprobe

Tan, Jiahui, Yin, Kai, Ouyang, Zhirong, Wang, Rongchen, Pan, Hongming, Wang, Zhijun, Zhao, Chuchang, Guo, Wei +1 more·2021·Analytical Chemistry

Abstract

Real-time in vivo optical imaging of kidney function is important for the diagnosis of renal diseases, such as acute kidney injury (AKI) and chronic kidney disease (CKD), with high morbidity and mortality worldwide. However, the reported optical imaging agents still have limitations for identifying AKI or CKD in the early stage due to their low sensitivity, poor tissue penetration, and significant background interference. Herein, an N -acetyl-β- d -glucosaminidase (NAG)-activatable second near-infrared (NIR-II) fluorescent nanoprobe (BOD-II-NAG-NP) is developed for monitoring the progression of drug-induced AKI and in vivo imaging of diabetes-caused CKD. NAG, as a biomarker of renal diseases, is able to specifically activate BOD-II-NAG-NP to release NIR-II fluorescence signals, enabling in vivo imaging of kidney dysfunctions in living mice. Importantly, such an active imaging mechanism allows BOD-II-NAG-NP to noninvasively detect the onset of drug-induced AKI at least 32 h earlier than the most existing assays, which indicates that BOD-II-NAG-NP has the potential to be an optical imaging agent for the early diagnosis of AKI. Moreover, NIR-II fluorescence produced by BOD-II-NAG-NP could deeply penetrate into the relatively thick layers of fat in diabetic nephropathy mice and provide in vivo imaging with high resolution, indicating that BOD-II-NAG-NP has clinical potential for precision diagnosis of CKD.

Integrity signals

Registry

Crossref · 10.1021/acs.analchem.1c03926

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In cisplatin-induced AKI models, BOD-II-NAG-NP enabled high-resolution imaging within 5 min post injection, with signals localized predominantly in the kidneys.

    “In cisplatin-induced AKI models, BOD-II-NAG-NP enabled high-resolution imaging within 5 min post injection, with signals localized predominantly in the kidneys.”
  • In the high-fat diet-induced diabetic nephropathy model, NIR-II fluorescence generated by BOD-II-NAG-NP could penetrate through the thicker fat layer, achieving clear imaging.

    “Notably, in the high-fat diet-induced diabetic nephropathy model, the NIR-II fluorescence generated by BOD-II-NAG-NP could penetrate through the thicker fat layer, achieving clear imaging.”
  • In vivo NIR-II imaging of NAG held clinical application prospects for achieving early and accurate diagnosis of AKI and CKD.

    “These results indicated that in vivo NIR-II imaging of NAG held clinical application prospects for achieving early and accurate diagnosis of AKI and CKD.”
  • Fluorescence titration revealed that addition of NAG led to significant enhancement of BOD-II-NAG fluorescence intensity at 1000 nm, with a detection limit of 0.72 mU/mL.

    “Fluorescence titration revealed that the addition of NAG led to a significant enhancement of its fluorescence intensity at 1000 nm, with a detection limit of 0.72 mU/mL.”
  • BOD-II-NAG was conjugated with mPEG-DSPE to form water-dispersible BOD-II-NAG-NP.

    “To improve biocompatibility, BOD-II-NAG was conjugated with mPEG-DSPE to form water-dispersible BOD-II-NAG-NP.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tan, J., Yin, K., Ouyang, Z., Wang, R., Pan, H., Wang, Z., Zhao, C., Guo, W., & Gu, X.
Affiliations
  • Fudan University (CN)
  • East China University of Science and Technology (CN)
Corresponding author
  • Guo, Wei
  • Gu, Xianfeng
Venue
Analytical Chemistry
Published
2021-11-23
Volume
93
Issue
48
Pages
16158-16165
ISSN
  • 0003-2700 (ISSN-L)
  • 1520-6882
OpenAlex
W3215218443
Cited by
52
References
44
Citations by year
2026: 17 · 2025: 13 · 2024: 6 · 2023: 8 · 2022: 8
FWCI
3.77
Type
journal article
Language
en
Open access
closed
Locations
  • Analytical Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Science and Technology Commission of Shanghai Municipality (2018SHZDZX03)
  • National Natural Science Foundation of China (21572039, 21874043, 21977018)
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Physical Sciences › Chemistry › Spectroscopy › Molecular Sensors and Ion Detection
  • Physical Sciences › Materials Science › Materials Chemistry › Luminescence and Fluorescent Materials
Keywords
drug-induced acute kidney injury, chronic kidney disease, diabetic nephropathy, N-acetyl-beta-D-glucosaminidase, early diagnosis of kidney disease, renal function monitoring
MeSH terms
Acetylglucosaminidase, Animals, Diabetes Mellitus, Pharmaceutical Preparations, Biomarkers, Mice, Renal Insufficiency, Chronic, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review